4-Morpholinecarbonyl chloride → HCID 10216398, 화합물
반응식
[CH3:1][O:2][C:3]1[CH:12]=[C:11]2[C:6]([CH2:7][CH2:8][CH:9]([N:13]([CH:17]3[CH2:22][CH2:21][NH:20][CH2:19][CH2:18]3)[CH2:14][CH2:15][CH3:16])[CH2:10]2)=[CH:5][CH:4]=1.[N:23]1([C:29](Cl)=[O:30])[CH2:28][CH2:27][O:26][CH2:25][CH2:24]1>ClCCl.CCN(C(C)C)C(C)C>[CH3:1][O:2][C:3]1[CH:12]=[C:11]2[C:6]([CH2:7][CH2:8][CH:9]([N:13]([CH2:14][CH2:15][CH3:16])[CH:17]3[CH2:18][CH2:19][N:20]([C:29]([N:23]4[CH2:28][CH2:27][O:26][CH2:25][CH2:24]4)=[O:30])[CH2:21][CH2:22]3)[CH2:10]2)=[CH:5][CH:4]=1참가 물질
5
반응 조건
- 온도
- 25 °C
실험 절차
To a solution of (7-methoxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-piperidin-4-yl-propyl-amine (200 μL of 0.025 M in dichloromethane, 50 μmole) was added 200 μL of 0.25 M solution of morpholine 4-carbonyl chloride in dichloromethane and 30 μL of DIEA. The solution was allowed to stir for 24 h at 25° C. under N2. Concentrated in vacuo. The final product was isolated by preparative RPHPLC (YMC Combiprep ODS-A column, 10-90% acetonitrile: water (0.1% TFA)) to afford {4-[(7-methoxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-propyl-amino]-piperidin-1-yl}-morpholin-4-yl-methanone 1 (11.9 mg), [M+H]+=461.
후처리
- concentrationConcentrated in vacuo
출처 및 근거
- ORD 기록
- ord-ad3cc854d19645fcb031ffaf8f373e3a
- 출처 데이터셋
- uspto-grants-2004_10
- 특허 번호
- US06806278B2
반응 노트
불러오는 중…